Pliant Therapeutics Overview

  • Founded
  • 2016

Founded
  • Status
  • Public

  • Employees
  • 114

Employees
  • Stock Symbol
  • PLRX

Stock Symbol
  • Share Price
  • $17.78

  • (As of Thursday Closing)

Pliant Therapeutics General Information

Description

Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 260 Littlefield Avenue
  • San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Pliant Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pliant Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.78 $18.38 $3.96 - $26.25 $896M 48.8M 449K -$2.90

Pliant Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 869,689 265,482 512,102
Revenue 9,719 7,572 41,817 57,052
EBITDA (112,613) (96,000) (40,335) (118)
Net Income (112,792) (97,263) (41,533) (631)
Total Assets 377,181 221,215 295,526 119,064
Total Debt 16,675 7,194 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pliant Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pliant Therapeutics‘s full profile, request access.

Request a free trial

Pliant Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Pliant Therapeutics‘s full profile, request access.

Request a free trial

Pliant Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therap
Biotechnology
San Francisco, CA
114 As of 2022
00000
00000000 00000

00000

or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000000000000
Watertown, MA
00 As of 0000
000.00
000000 - 000 000.00

000000

nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
Norcross, GA
00 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pliant Therapeutics Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eloxx Pharmaceuticals Formerly VC-backed Watertown, MA 00 000.00 000000 - 000 000.00
00000000 000000000 Corporation Norcross, GA 00 000000000000
000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 00000 000000000 00000
000000000 (0000000 Formerly VC-backed Mechelen, Belgium 0000 00.000 000000000 00.000
You’re viewing 5 of 19 competitors. Get the full list »

Pliant Therapeutics Patents

Pliant Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220177468-A1 Integrin inhibitor and uses thereof Pending 19-Nov-2020 0000000000
AU-2021268889-A1 Treatment of respiratory diseases with amino acid compounds Pending 07-May-2020
AU-2020408067-A1 Combination treatment of liver diseases using integrin inhibitors Pending 20-Dec-2019 00000000000
CA-3164941-A1 Combination treatment of liver diseases using integrin inhibitors Pending 20-Dec-2019 00000000000
AU-2020405182-A1 Combination treatment of liver diseases using integrin inhibitors Pending 20-Dec-2019 A61K31/4375
To view Pliant Therapeutics’s complete patent history, request access »

Pliant Therapeutics Executive Team (15)

Name Title Board Seat Contact Info
Bernard Coulie MD Chief Executive Officer & Board Member
Keith Cummings MD Chief Financial Officer
Hans Hull JD Chief Business Officer
Éric Lefebvre MD Chief Medical Officer
Dean Sheppard MD Scientific Co-Founder & Member of Scientific Advisory Board
You’re viewing 5 of 15 executive team members. Get the full list »

Pliant Therapeutics Board Members (13)

Name Representing Role Since
Bernard Coulie MD Pliant Therapeutics Chief Executive Officer & Board Member 000 0000
David Pyott Self Board Member 000 0000
Gayle Crowell Self Board Member 000 0000
Hoyoung Huh Ph.D Self Board Member 000 0000
John Curnutte MD Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Pliant Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pliant Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pliant Therapeutics‘s full profile, request access.

Request a free trial